Gleicher, Norbert
Patrizio, Pasquale
Mochizuki, Lyka
Barad, David H.
Article History
Received: 11 January 2023
Accepted: 2 March 2023
First Online: 8 March 2023
Declarations
:
: All data were obtained already deidentified and the protocol of the study was approved by local Institutional Review Boards (IRBs) in New York (Name: IRB of the Center for Human Reproduction) as well as Israel (Name: IRB of Tel-Aviv University School of Medicine). The methodology of the study was carried out in accordance with all relevant guidelines and regulations in accordance with the Declaration of Helsinki. Because data was received anonymized, there was no possibility to obtain individual consents.U.S. patients had, however, signed individual consents that permitted the use of their medical records for research purposes as long as their identity was not revealed, and their medical records remained confidential. Both conditions were met. The study did not involve patients below the age of 18.
: Not applicable.
: Dr. Gleicher and Dr. Barad are listed as co-inventor on several U.S. patents, none in any way related to here presented manuscript. They also received research support, travel funds, and speaker honoraria from several pharmaceutical and medical device companies, though, again, none related to here presented subjects and manuscript. Dr. Gleicher is a shareholder in Fertility Nutraceuticals and receives royalty payments from Fertility Nutraceuticals LLC. Dr. Patrizio reports no competing interests.